Genomic Health Inc. (GHDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.66-0.07 (-0.24%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close29.73
Bid22.58 x 200
Ask32.00 x 100
Day's Range29.29 - 29.84
52wk Range20.54 - 35.79
1y Target EstN/A
Market Cap990.12M
P/E Ratio (ttm)-35.91
Avg Vol (3m)212,423
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • StreetAuthority Network11 days ago

    This Innovative Healthcare Stock Belongs In My Portfolio -- What About Yours?

    Nestled within the beauty of Maine's Acadia National Park, on the picturesque Mount Desert Island, is a place known to many scientists and health care investors as the place where the term "

  • PR Newswire12 days ago

    Genomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ™ Liquid Biopsy Mutation Panel

    REDWOOD CITY, Calif., Oct. 11, 2016 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced results from its successfully completed analytical validation study of Oncotype SEQ™ Liquid Select, which demonstrated that this liquid biopsy mutation panel is highly sensitive, specific and reproducible. To provide transparent and clinically meaningful performance standards, the analytical performance for Oncotype SEQ is reported on a per-sample basis rather than a per-DNA base measure. "The high specificity, sensitivity and reproducibility of Oncotype SEQ validated in this study ensures reliable and actionable liquid biopsy test results that physicians can routinely use in clinical practice to help drive precision medicine and enable patients to make more informed treatment decisions," said Phil Febbo, M.D., chief medical officer, Genomic Health.

  • PR Newswire13 days ago

    Multiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients

    REDWOOD CITY, Calif., Oct. 10, 2016 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced results from eight Oncotype DX® Breast Recurrence Score™ (RS) presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, highlighting superior clinical evidence in identifying which patients with node-negative and node-positive invasive breast cancer should be treated with chemotherapy. Specifically, prospective clinical outcomes in more than 7,400 patients with node-positive invasive breast cancer from two independent studies show excellent survival in women with RS results less than 18. "The ESMO presentations continue to reinforce that Oncotype DX provides unique and unsurpassed value beyond tumor size and tumor grade for invasive breast cancer patients with node-negative and certain patients with node-positive disease," said Steven Shak, M.D., chief scientific officer, Genomic Health.